Stem Cell Stocks

On Sunday evening, 60 Minutes broadcast an extensive report on stem cell scams. It reported on companies around the world that make outrageous claims with regards to the treatment and cures that stem cells can provide. Numerous people who have incurable diseases are desperately looking for cures, and are being taking advantage of by charlatans purporting to solve all their medical issues.

However, stem cells are being used currently for medical treatments. Look at bone marrow transplants that are used to treat leukemia utilizing adult stem cells. Scientists are actively looking at stem cells to treat diseases such as cancer, Parkinson's disease, and spinal cord injuries.

There are actually many publicly traded companies involved in stem cell research. WallStreetNewsNetwork.com has turned up over 20 stem cell stocks, half of which are currently profitable.

Integra Lifesciences Holdings (IART) is a New Jersey based company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The stock trades at 17 times current earnings, and 7.5 times forward earnings. However, earnings for the latest quarter were down 31.8%.

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with an $13.7 billion market capitalization that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a price to earnings ratio of 92 and a forward PE of 45. Earnings for the latest quarter were up an amazing 135.2% on a 44% rise in revenues.

Cellgene (CELG) is a $29.8 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the company's main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received a patent on placental stem cell recovery. The stock sports a PE ratio of 28 and a forward PE of 15. Quarterly earnings were up 32.7% on a 37% revenue increase.

For a free list of over twenty stem cell stocks which you can download, sort, and update, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Many Cord Blood Companies Experiencing Double Digit Growth

A report called 'Capitalizing on Opportunities in Cord Blood Industry Growth' was just released by MarketResearch.com, which describes how a certain sector of blood banks are experiencing a very fast growth rate, ranging from 17% per year to 25% per year. The 201 page report is available for download for $3,995. This industry has got the attention of billionaires, such as Richard Branson, of Virgin Records and Virgin Atlantic Airways fame. He created Virgin Health, a cord blood bank.

So what is cord blood? Cord blood is blood that comes from the umbilical cords of babies, and contains a significant amount of hematopoietic stem cells. Specialized cord blood banks store this blood. Cord blood stem cells are considered far superior to stem cells from bone marrow. Cord blood of a baby is preserved in the event it may be needed at some point in the future for treatment of the cancer or genetic disease of the child or the child's siblings. Many diseases have been treated with cord blood. Information on cord blood and how it is collected, stored, and used, is available at CordBloodStocks.com.

Investors have two options when investing in this industry. They can own the stocks of the cord blood banks or own the companies that use cord blood to develop cures and produce extraction and storage products. One that falls into the second category is PerkinElmer, Inc. (PKI), which owns ViaCell, a Cambridge, Massachusetts company which sells ViaCord, a product which is used to preserve baby's umbilical cord blood. They also research and other therapeutic uses of umbilical cord blood-derived and adult-derived stem cells. The stock trades at 10 times forward earnings and pays a decent yield of 1.5%.

Baxter International Inc. (BAX) makes blood collection bags for umbilical cord blood and develop adult stem-cell therapies. They also own a patent for assembling and methods to process cord blood in a sterile fashion to avoid exposure to bacterial contamination and to disburse the introduction of cryopreservation solution into cord blood at a desired rate, thereby avoiding damage or trauma to the cord blood cells. The stock has a forward price to earnings ratio of 10 and sports a yield of 2.7%.

Celgene (CELG) is a New Jersey company that is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. They own LifeBank USA, a cord blood bank. The stock has a forward PE of 14.

Amgen Inc. (AMGN) is also funding research into cord blood extraction, preservation, and storage. The stock has a forward PE of 10 and carries a yield of 2.0%.

China Cord Blood Corporation (CO) provides cord blood collection, and stem cell storage services. The company is based in Beijing, China. The stock trades at 9 times earnings.

For a free list of cord blood and stem cell stocks, which can be downloaded, updated, and sorted, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

U of Colorado Opens Cord Blood Bank: What About Cord Blood Stocks

University of Colorado recently opened a public cord blood bank, funded by the federal government. Donations are accepted from almost anyone and the cord blood is available to those in need.

Cord blood is blood that comes from the umbilical cords of babies, and contains a significant amount of hematopoietic stem cells. Specialized cord blood banks, both private and public, are available to store this blood. Cord blood stem cells are considered far superior to stem cells from bone marrow. Parents often have their baby's cord blood preserved in the event it may be needed at some point in the future for treatment of their child's or the child's sibling's cancer or genetic disease. Numerous diseases have been treated with cord blood. For a lot more detail on cord blood and how it is collected, stored, and used, go to CordBloodStocks.com.

The cord blood industry continues to grow. Even Richard Branson, of Virgin Records and Virgin Atlantic Airways fame, set up Virgin Health, a cord blood bank. Investors have a two-pronged approach to this investment industry: owning the stocks of the cord blood banks or owning the companies that use cord blood to develop cures.

PerkinElmer, Inc. (PKI) owns ViaCell, a Cambridge, Massachusetts company which sells ViaCord, a product which is used to preserve baby's umbilical cord blood. They also research and other therapeutic uses of umbilical cord blood-derived and adult-derived stem cells. The stock trades at 12 times forward earnings and pays a yield of 1.3%.

Baxter International Inc. (BAX) makes blood collection bags for umbilical cord blood and develop adult stem-cell therapies. They also own a patent for assembling and methods to process cord blood in a sterile fashion to avoid exposure to bacterial contamination and to disburse the introduction of cryopreservation solution into cord blood at a desired rate, thereby avoiding damage or trauma to the cord blood cells. The stock has a forward price to earnings ratio of 12 and pays a yield of 2.3%.

Celgene (CELG) is a New Jersey company that is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. They own LifeBank USA, a cord blood bank. The forward PE is 14, but does not pay a dividend.

Amgen Inc. (AMGN) is also funding research into cord blood extraction, preservation, and storage. The stock has a forward PE of 10 and sports a yield of 2.1%.

China Cord Blood Corporation (CO) provides cord blood collection, and stem cell storage services. The company is based in Beijing, China. The stock does not pay a dividend but trades at 12 times earnings.

For a free list of cord blood and stem cell stocks, which can be downloaded, updated, and sorted, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Stem Cell Funding Ban Reversed: What About the Stocks?

Last week was a busy week for stem cells. The suspension of Federal funding for stem cell research has just been overturned by a United States Appeals Court. The two to one ruling last week said that the law against Federal funding was ambiguous. In addition, Dr. Paul Sharpe spoke at the First International Conference on Dental and Craniofacial Stem Cells in New York last week. He discussed the use of regenerative dentistry to regrow teeth with dental stem cells.

Research has been continuing into the use of stem cells for gene therapy and the treatment of Parkinson’s disease, heart disease, diabetes, multiple sclerosis, arthritis, and many other medical conditions. Stem cells can come from various sources including embryos, cord blood, which is the blood from umbilical cords, and even in baby teeth. There are several publicly traded companies in the stem cell field, according to the free list of stem cell stocks at WallStreetNewsNetwork.com.

For example, Alexion Pharmaceuticals (ALXN) is a Connecticut based company with an $8.9 billion market capitalization that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a price to earnings ratio of 93 and a forward PE of 32.

Cellgene (CELG) is a $27.4 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the company's main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received a patent on placental stem cell recovery. The stock sports a PE ratio of 31 and a forward PE of 14.

Integra Lifesciences Holdings (IART) is a New Jersey based $1.5 billion market cap company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The stock trades at 24 times current earnings, and 16 times forward earnings.

For a free list of over a dozen stem cell stocks which you can download, sort, and update, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Stem Cell Stocks Are Growing

According to the latest Journal of the Congress of Neurological Surgeons Research, Neurosurgery, bone marrow stem cells derived from a patient's own bone marrow were safely used in pediatric patients with severe traumatic brain injury, according to results of a Phase I clinical trial at The University of Texas Health Science Center at Houston.

Research has been continuing into the utilization of stem cells for gene therapy and the treatment of Parkinson’s disease, heart disease, diabetes, multiple sclerosis, arthritis, and many other medical conditions. Stem cells can come from various sources including embryos, cord blood, which is the blood from umbilical cords, and even in baby teeth. WallStreetNewsNetwork.com just updated its free downloadable list of over ten stem cell stocks. Can one of these provide a cure for your portfolio?

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with an $8.9 billion market capitalization that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a PE of 94 and a forward PE of 33.

Cellgene (CELG) is a $24.7 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the company's main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received a patent on placental stem cell recovery. The stock sports a PE ratio of 28 and a forward PE of 13.

Integra Lifesciences Holdings (IART) is a New Jersey based $1 billion market cap company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The stock trades at 22 times earnings, and 14.5 times forward earnings.

For a database of over a dozen stem cell stocks which you can download, sort, and update, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

First US Trial of Embryonic Stem Cells in Humans

The Food and Drug Administration has given the go ahead to Geron (GERN) to use human embryonic stem cells in human patients. The trial study will be sued to treat patients with spinal injuries. Previous studies have shown that paralyzed rats have achieved some movement after treatment.

Geron, which has expended $170 million on stem cell research, was up about 6% today on the news. The stock generated a quarterly loss of 73 cents for the latest reported quarter, however, revenues were up 447% during the same time frame. The company will report earnings on October 28. This debt free company has $1.19 in cash per share.

Research has been continuing to utilize stem cells for gene therapy and the treatment of Parkinson’s disease, heart disease, diabetes, multiple sclerosis, arthritis, macular degeneration, and many other medical conditions. Stem cells can come from various sources including embryos, cord blood, which is the blood from umbilical cords, and even in baby teeth. WallStreetNewsNetwork.com developed a downloadable list of over ten stem cell stocks. Hopefully your portfolio will receive a cure with one of these companies. Here is a list of a few opportunities.

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with a $6 billion market cap that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The stock has a PE of 20 and a forward PE of 28.

Cellgene (CELG) is a $26 billion market cap company involved in the discovery and production, of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. The company also received patent on placental stem cell recovery. The stock sports a PE of 31 and a forward PE of 17.

Integra LifeSciences Holdings (IART) is a New Jersey based $1 billion market cap company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The P/E is 19, and the forward PE is 13.

For an Excel database of over ten stem cell stocks which you can download, sort, and change, go to WallStreetNewsNetwork.com.

Disclosure: Author does not own any of the above at the time the article was written.

By Stockerblog.com